Pharyngeal muscles

The pharyngeal muscles are a complex group of skeletal muscles organized into circular constrictors and longitudinal elevators that facilitate critical physiological processes, including swallowing (deglutition), speech production, and the maintenance of upper airway patency [1][2]. During the pharyngeal phase of swallowing, these muscles contract in a highly coordinated sequence to propel the food bolus into the esophagus while elevating the larynx and closing the glottis to protect the respiratory tract from aspiration [1][3]. Dysfunction of the pharyngeal musculature is a primary driver in several clinical conditions, most notably obstructive sleep apnea (OSA), where reduced dilator muscle tone leads to nocturnal airway collapse, and oropharyngeal dysphagia, which can result from neurological damage or primary myopathies like oculopharyngeal muscular dystrophy [2][4]. Although the term "pharyngeal muscles" refers to an anatomical tissue structure rather than a single molecular target or receptor, these muscles are the site of action for various pharmacological agents that modulate neuromuscular transmission [5]. For example, botulinum toxin is frequently used therapeutically to relax the cricopharyngeal muscle in cases of achalasia, while acetylcholinesterase inhibitors like pyridostigmine are utilized to improve muscle strength in autoimmune conditions like myasthenia gravis that impair pharyngeal function [5][6].

Other names

Muscles of the pharynxPharyngeal musculaturePharyngeal constrictorsPharyngeal elevators

Drugs affecting the pharyngeal muscles typically work by modulating neuromuscular transmission at the nicotinic acetylcholine receptors located within the motor endplates of the muscle tissue. This includes inhibiting acetylcholine release (neurotoxins), inhibiting acetylcholinesterase to increase acetylcholine availability (cholinergics), or competitively blocking receptors (neuromuscular blockers).